Stock AnalizVertex Pharmaceuticals Inc. / MA VRTX
Biotechnology: Pharmaceutical Preparations · IPO 1991 · data as of November 13, 2026
Vertex Pharmaceuticals Inc. / MA (VRTX) is a healthcare company listed in the US with a market value of about $136.6B. In the twelve months to September 30, 2026 it had revenue of $13.0B and net income of $4.0B, a net margin of 30.7%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 34.7, a price to free cash flow of 42.6, 5-year revenue growth of 14% a year, a 5-year average ROIC of 16%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 53% below the current price.
Score: 2.4 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.0B | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B | $6.2B | $4.2B | $3.0B | $2.5B | $1.7B |
| Net income | $4.0B | $4.0B | -$536M | $3.6B | $3.3B | $2.3B | $2.7B | $1.2B | $2.1B | $263M | -$112M |
| Free cash flow | $3.2B | $3.2B | -$790M | $3.3B | $3.9B | $2.4B | $3.0B | $1.5B | $1.2B | $746M | $180M |
| EPS (diluted) | $15.53 | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | $-0.46 |
| Net margin | 30.7% | 32.9% | -4.9% | 36.7% | 37.2% | 30.9% | 43.7% | 28.3% | 68.8% | 10.6% | -6.6% |
| ROIC | — | 17.3% | -1.0% | 17.6% | 23.6% | 22.7% | 27.5% | 16.3% | 11.3% | 4.8% | 0.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 28 analysts is $595.36, 11% above the current price; targets range from $350.00 to $725.00; the consensus rating is “Buy”; expected EPS is $18.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Vertex Pharmaceuticals Inc. / MA’s P/E ratio?
About 34.7, based on the last twelve months of diluted earnings per share (forward P/E about 28.7).
Is Vertex Pharmaceuticals Inc. / MA stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 53% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Vertex Pharmaceuticals Inc. / MA pay a dividend?
Not currently.
Is Vertex Pharmaceuticals Inc. / MA a good stock to buy?
We do not give buy or sell advice. Vertex Pharmaceuticals Inc. / MA scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.